Rigel Pharmaceuticals (RIGL) Cash & Current Investments (2010 - 2026)

Rigel Pharmaceuticals has reported Cash & Current Investments for 17 years, with the latest figure at $146.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 90.25% year-over-year to $146.7 million; the trailing twelve-month figure through Mar 2026 stood at $146.7 million (up 90.25% YoY), and the FY2025 full-year result was $155.0 million, up 100.4% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $146.7 million, down from $155.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $155.0 million in Q4 2025, with the low at $49.1 million in Q2 2024.
• Average Cash & Current Investments over 5 years is $84.7 million, with a median of $77.1 million recorded in 2025.
• Peak annual rise in Cash & Current Investments reached 173.27% in 2022, while the deepest fall reached 53.42% in 2022.
• Tracing RIGL's Cash & Current Investments over 5 years: stood at $58.2 million in 2022, then retreated by 2.19% to $56.9 million in 2023, then soared by 35.81% to $77.3 million in 2024, then surged by 100.4% to $155.0 million in 2025, then fell by 5.34% to $146.7 million in 2026.
• The last three Cash & Current Investments figures came in at $146.7 million (Q1 2026), $155.0 million (Q4 2025), and $137.1 million (Q3 2025), per Business Quant data.

Peer Comparison